Based on the PolyPeptide Group AG stock forecast from 0 analysts, the average analyst target price for PolyPeptide Group AG is not available over the next 12 months. PolyPeptide Group AG’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of PolyPeptide Group AG is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, PolyPeptide Group AG’s stock price was GBP 16.72. PolyPeptide Group AG’s stock price has changed by -5.22% over the past week, -32.85% over the past month and -37.35% over the last year.
No recent analyst target price found for PolyPeptide Group AG
No recent average analyst rating found for PolyPeptide Group AG
Company Overview PolyPeptide Group AG
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the Americas, the Asia Pacific, and internationally. It focuses on peptide- and oligonucleotide-based therapies for pharma and biotech customers. The company also develops and manufactures active ingredients for therapies that range from the treatment of metabolic diseases, such as diabetes or obesity, as well as cancer and cardiovascular, or neurological disorders. In addition, it engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. Further, the company is involved in manufacturing peptides for commercially approved peptide therapeutics. Additionally, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. The company offers regulatory affair support services. It has a collaboration agreement with Numaferm for peptide development and production The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V. Address: Dammstrasse 19, Zug, Switzerland, 6300 Read Less
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the Americas, the Asia Pacific, and internationally. It focuses on peptide- and oligonucleotide-based therapies for pharma and biotech customers. The company also develops and manufactures...Read More
Frequently Asked Questions About PolyPeptide Group AG (0AAJ:LSE) Stock
Stock Target Advisor's fundamental analysis for PolyPeptide Group AG's stock is Neutral.
Unfortunately we do not have enough data on 0AAJ:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 0AAJ:LSE's stock to indicate what its average analyst target is.
0AAJ:LSE stock's Price/Earning ratio is 0.15.
Based on this 0AAJ:LSE may be a overvalued for its sector.
The last closing price of 0AAJ:LSE's stock was GBP 16.72.
Unfortunately we do not currently have any market capitalization data for 0AAJ:LSE's stock.
Unfortunately we do not have enough analyst data on 0AAJ:LSE's stock to indicate whether its price will go up or not.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
There is nothing we particularly dislike
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 0AAJ:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
